FDA Fast Track Designation for BBO-11818 for Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

“Receiving Fast Track designation from the FDA for BBO-11818 in KRAS-mutant pancreatic ductal adenocarcinoma reflects the importance and urgency of accelerating the development of our pan-KRAS inhibitor in this serious disease,” said Yong Ben, MD, Chief Medical and Development Officer of BBOT. “Pancreatic cancer remains one of the most difficult-to-treat malignancies. KRAS mutations are present in the vast majority of cases, yet patients have had few targeted options. This designation will help us collaborate closely with the FDA to advance BBO-11818 as efficiently as possible for patients who need new options.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib